Nila | $2,400,000 | (Oct 17, 2025)
Upciti | $20,000,000 | (Oct 17, 2025)
MGT Insurance | $21,600,000 | (Oct 17, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
Sonic Fire Tech | $3,500,000 | (Oct 17, 2025)
Strella | $14,000,000 | (Oct 17, 2025)
Temple Digital Group | $5,000,000 | (Oct 17, 2025)
ATDev | $3,000,000 | (Oct 17, 2025)
Jack and Jill | $20,000,000 | (Oct 17, 2025)
Brook Health | $28,000,000 | (Oct 17, 2025)
Vega Health | $4,000,000 | (Oct 17, 2025)
ExaCare AI | $30,000,000 | (Oct 17, 2025)
Daylight(US) | $75,000,000 | (Oct 17, 2025)